DiaPep277® and immune intervention for treatment of type 1 diabetes

Clinical Immunology

Volumn 149, Issue 3, 2013, Pages 307-316

  Schloot, Nanette C ^a   Cohen, Irun R ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

C peptide; Immunotherapy; T cells; Type 1 diabetes

Indexed keywords

ANTIINFLAMMATORY AGENT; ATORVASTATIN; C PEPTIDE; C REACTIVE PROTEIN; CHAPERONIN 60; DIAPEP 277; DIAPEP277; ETANERCEPT; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MANNITOL; OTELIXIZUMAB; PEPTIDE; PLACEBO; PROINSULIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STREPTOZOCIN; TEPLIZUMAB; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL FUNCTION; CELL LOSS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DIABETES CONTROL; DIABETIC PATIENT; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS INFECTION; FIRST DEGREE RELATIVE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; GLYCEMIC CONTROL; GOLD STANDARD; HLA SYSTEM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; INTERVENTION STUDY; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; META ANALYSIS; MULTICENTER STUDY (TOPIC); MYCOBACTERIUM TUBERCULOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PANCREAS ISLET CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REHABILITATION; REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION; TEST MEAL; THERAPY EFFECT; TREATMENT DURATION; VITAL SIGN;

C-PEPTIDE; IMMUNOTHERAPY; T CELLS; TYPE 1 DIABETES;

AUTOANTIBODIES; AUTOIMMUNITY; C-PEPTIDE; CHAPERONIN 60; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84887015900     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.09.001     Document Type: Review

References (62)

1. Rewers M., LaPorte R.E., King H., Tuomilehto J. Trends in the prevalence and incidence of diabetes: insulin-dependent diabetes mellitus in childhood. World Health Stat. Q. 1988, 41:179-189.
2. Rewers M., Norris J., Kretowski A. Epidemiology of type 1 diabetes (revised 11/3/2010), chapter 9. Online textbook type 1 diabetes. Cell. Mol. Clin. Immunol. 2010, (http://barbaradaviscenter.org/).
3. Hawa M.I., Kolb H., Schloot N.C., Beyan H., Paschou S.A., Buzzetti R., Mauricio D., De Leiva A., Yderstraede K., Beck-Neilsen H., Tuomilehto J., Sarti C., Thivolet C., Hadden D., Hunter S., Schernthaner G., Scherbaum W.A., Williams R., Brophy S., Pozzilli P., Leslie R.D. Action LADA consortium, adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 2013, 36:908-913.
4. EURODIAB ACE Study Group Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000, 355:873-876.
5. Harjutsalo V., Sjoberg L., Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371:1777-1782.
6. Fourlanos S., Varney M.D., Tait B.D., Morahan G., Honeyman M.C., Colman P.G., Harrison L.C. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008, 31:1546-1549.
7. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch. Dis. Child. 2008, 93:512-517.
8. Steffes M.W., Sibley S., Jackson M., Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26:832-836.
9. Mineo D., Pileggi A., Alejandro R., Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care 2009, 32:1563-1569.
10. Palmer P.J., Fleming G.A., Greenbaum C.J., Herold K.C., Jansa L.D., Kolb H., Lachin J.M., Polonsky K.S., Pozzilli P., Skyler J.S., Steffes M.W. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004, 53:250-264.
11. Diabetes prevention trial study grout DPT 1 Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 2002, 346:1685-1691.
12. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., Cuthbertson D., Rafkin-Mervis L.E., Chase H.P., Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28:1068-1076.
13. Näntö-Salonen K., Kupila A., Simell S., Siljander H., Salonsaari T., Hekkala A., Korhonen S., Erkkola R., Sipilä J.I., Haavisto L., Siltala M., Tuominen J., Hakalax J., Hyöty H., Ilonen J., Veijola R., Simell T., Knip M., Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372:1746-1755.
14. Skyler J.S. Primary and secondary prevention of type 1 diabetes. Diabet. Med. 2013, 30:161-169.
15. Gale E.A., Bingley P.J., Emmett C.L., Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group, European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363:925-931.
16. Greenbaum C.J., Mandrup-Poulsen T., McGee P.F., Battelino T., Haastert B., Ludvigsson J., Pozzilli P., Lachin J.M., Kolb H. Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group, mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008, 31:1966-1971.
17. Lernmark A., Larsson H.E. Immune therapy in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9:92-103.
18. Mastrandrea L., Yu J., Behrens T., Buchlis J., Albini C., Fourtner S., Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009, 32:1244-1249.
19. Rother K.I., Brown R.J., Morales M.M., Wright E., Duan Z., Campbell C., Hardin D.S., Popovic J., McEvoy R.C., Harlan D.M., Orlander P.R., Brod S.A. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care 2009, 32:1250-1255.
20. Martin S., Herder C., Schloot N.C., Koenig W., Heise T., Heinemann L., Kolb H. DIATOR Study Group. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One 2011, 11:e17554.
21. Wierzbicki A.S. Atorvastatin. Expert. Opin. Pharmacother. 2001, 5:819-830.
22. Strom A., Kolb H., Martin S., Herder C., Simon M.C., Koenig W., Heise T., Heinemann L., Roden M., Schloot N.C. DIATOR Study Group, Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One 2012, 7:e33108.
23. Larsen C.M., Faulenbach M., Vaag A., Vølund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
24. Pfleger C., Mortensen H.B., Hansen L., Herder C., Roep B.O., Hoey H., Aanstoot H.J., Kocova M., Schloot N.C. Hvidøre Study Group on Childhood Diabetes, Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008, 57:929-937.
25. Pickersgill L.M., Mandrup-Poulsen T. On behalf of the AIDA study group, the anti-interleukin-1 in type 1 diabetes action trial-background and rationale. Diabetes Metab. Res. Rev. 2009, 25:321-324.
26. Moran A., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Greenbaum C.J., Herold K.C., Marks J.B., Raskin P., Sanda S., Schatz D., Wherrett D.K., Wilson D.M., Krischer J.P., Skyler* J.S., Type 1 Diabetes TrialNet Canakinumab Study Group**, Pickersgill L., de Koning E., Ziegler A.-G., Böhm B., Badenhoop K., Schloot N.C., Bak J.F., Pozzilli P., Mauricio D., Donath M.Y., Castaño L., Wägner A., Lervang H.H., Perrild H., Mandrup-Poulsen* T. On behalf of the AIDA Study Group Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized double-masked, placebo-controlled trials. Lancet 2013, 381:1905-1915.
27. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.F., Pipeleers D., Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
28. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
29. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., Bode B., Aronoff S., Holland C., Carlin D., King K.L., Wilder R.L., Pillemer S., Bonvini E., Johnson S., Stein K.E., Koenig S., Herold K.C., Daifotis A.G. Protégé Trial Investigators, Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
30. Lebastchi J., Deng S., Lebastchi A.H., Beshar I., Gitelman S., Willi S., Gottlieb P., Akirav E.M., Bluestone J.A., Herold K.C. Immune therapy and β-cell death in type 1 diabetes. Diabetes 2013, 62:1676-1680.
31. Martin S., Wolf-Eichbaum D., Duinkerken G., Scherbaum W.A., Kolb H., Noordzij J.G., Roep B.O. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 2001, 345:1036-1040.
32. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Type 1 Diabetes TrialNet Anti-CD20 Study Group, Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
33. Ludvigsson J., Faresjö M., Hjorth M., Axelsson S., Chéramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., Lindh A., Nilsson N.O., Aman J., Ortqvist E., Zerhouni P., Casas R. GAD treatment and insulin secretion in recent-onset type 1diabetes. N. Engl. J. Med. 2008, 359:1909-1920.
34. Ludvigsson J., Krisky D., Casas R., Battelino T., Castaño L., Greening J., Kordonouri O., Otonkoski T., Pozzilli P., Robert J.J., Veeze H.J., Palmer J. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 2012, 366:433-442.
35. Roep B.O., Solvason N., Gottlieb P.A., Abreu J.R., Harrison L.C., Eisenbarth G.S., Yu L., Leviten M., Hagopian W.A., Buse J.B., von Herrath M., Quan J., King R.S., Robinson W.H., Utz P.J., Garren H. BHT-3021 Investigators, Steinman L, plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci. Transl. Med. 2013, 5:191ra82.
36. Elias D., Reshef T., Birk O.S., van der Zee R., Walker M.D., Cohen I.R. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3088-3091.
37. Elias D., Cohen I.R. Peptide therapy for diabetes in NOD mice. Lancet 1994, 343:704-706.
38. Quintana F.J., Cohen I.R. The HSP60 immune system network. Trends Immunol. 2011, 32:89-95.
39. Kaufmann S.H. Heat shock proteins and the immune response. Immunol. Today 1990, 11:129-136.
40. Merbl Y., Zucker-Toledano M., Quintana F.J., Cohen I.R. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J. Clin. Invest. 2007, 117:712-718.
41. Quintana F.J., Hagedorn P.H., Elizur G., Merbl Y., Domany E., Cohen I.R. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc. Natl. Acad. Sci. U. S. A. 2004, 5(101 Suppl. 2):14615-14621.
42. Quintana F.J., Rotem A., Carmi P., Cohen I.R. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J. Immunol. 2000, 165:6148-6155.
43. Elias D., Cohen I.R. The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin. Diabetes 1996, 45:1168-1172.
44. Ablamunits V., Elias D., Reshef T., Cohen I.R. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J. Autoimmun. 1998, 11:73-81.
45. Elias D., Cohen I.R. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes 1995, 44:1132-1138.
46. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277®): a randomised, double-blind, phase II trial. Lancet 2001, 358:1749-1753.
47. Zanin-Zhorov A., Tal G., Shivtiel S., Cohen M., Lapidot T., Nussbaum G., Margalit R., Cohen I.R., O Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: effects on signaling, chemotaxis, and inflammation. J. Immunol. 2005, 175:276-285.
48. Zanin-Zhorov A., Nussbaum G., Franitza S., Cohen I.R., Lider O. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. FASEB J. 2003, 17:1567-1569.
49. Tuccinardi D., Fioriti E., Manfrini S., D'Amico E., Pozzilli P. DiaPep277® peptide therapy in the context of other immune intervention trials in type 1 diabetes. Expert. Opin. Biol. Ther. 2011, 11:1233-1240.
50. Raz I., Avron A., Tamir M., Metzger M., Symer L., Eldor R., Cohen I.R., Elias D. Treatment of new-onset type 1 diabetes with peptide DiaPep277® is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab. Res. Rev. 2007, 23:292-298.
51. Huurman V.A., van der Meide P., Duinkerken G., Willemen S., Cohen IR I.R., Elias D., Roep B.O. Immunological efficacy of heat shock protein 60 peptide DiaPep277® therapy in clinical type I diabetes. Clin. Exp. Immunol. 2008, 152:488-497.
52. Schloot N.C., Meierhoff G., Lengyel C., Vandorfi G., Takacs J., Panczel P., Barkai L., Madacsy L., Oroszlan T., Kovacs P., Suto G., Battelino T., Hosszufalusi N., Jermendy G. Effect of heat shock protein peptide DiaPep277® on β-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab. Res. Rev. 2007, 23:276-285.
53. Buzzetti R., Cernea S., Petrone A., Capizzi M., Spoletini M., Zampetti S., Guglielmi C., Venditti C., Pozzilli P. DiaPep Trialists Group. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277®: an exploratory study. Diabetes 2011, 60:3067-3072.
54. Pozzilli P., Guglielmi C. Immunomodulation for the prevention of SPIDDM and LADA. Ann. N. Y. Acad. Sci. 2006, 1079:90-98.
55. Lazar L., Ofan R., Weintrob N., Avron A., Tamir M., Elias D., Phillip M., Josefsberg Z. Heat-shock protein peptide DiaPep277® treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab. Res. Rev. 2007, 23:286-291.
56. Mallone R., Mannering S.I., Brooks-Worrell B.M., Durinovic-Belló I., Cilio C.M., Wong F.S., Schloot N.C. T-Cell Workshop Committee, Immunology of Diabetes Society, Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 2011, 163:33-49.
57. Mannering S.I., Wong F.S., Durinovic-Belló I., Brooks-Worrell B., Tree T., Cilio C.M., Schloot N.C., Mallone R. Immunology of Diabetes Society T-Cell Workshop Committee. Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes. Clin. Exp. Immunol. 2010, 162:197-209.
58. James E.A., Mallone R., Schloot N.C., Gagnerault M.C., Thorpe J., Fitzgerald-Miller L., Reichow J., Wagner R., Pham M.N., Jospe N., Lou O., Gottlieb P.A., Brooks-Worrell B., Durinovic-Belló I. T-Cell Workshop Committee, Immunology of Diabetes Society, Immunology of Diabetes Society T-Cell Workshop: HLA class II tetramer-directed epitope validation initiative. Diabetes Metab. Res. Rev. 2011, 27:727-736.
59. Brooks-Worrell B., Tree T., Mannering S.I., Durinovic-Bello I., James E., Gottlieb P., Wong S., Zhou Z., Yang L., Cilio C.M., Reichow J., Menart B., Rutter R., Schreiner R., Pham M.N., Petrich de Marquesini L., Lou O., Scotto M., Mallone R., Schloot N N.C. T-Cell Workshop Committee, Immunology of Diabetes Society, Comparison of cryopreservation methods on T-cell responses to islet and control antigens from type 1 diabetic patients and controls. Diabetes Metab. Res. Rev. 2011, 27:737-745.
60. Huurman V.A., Decochez K., Mathieu C., Cohen I.R., Roep B.O. Therapy with the hsp60 peptide DiaPep277® in C-peptide positive type 1 diabetes patients. Diabetes Metab. Res. Rev. 2007, 23:269-275.
61. Pfleger C., Meierhoff G., Kolb H., Schloot N.C. p520/521 Study Group, association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. J. Autoimmun. 2010, 34:127-135.
62. Dagan S., Ziegler A.G., Pozzilli P.G., Linn T., Schernthaner G., Bonnici F., Elias D., Eren R., Cohen I.R., Raz I., Group S. Recent Data from DIA-AID 1, a Global Phase III Clinical Study in Newly Diagnosed Type 1 Diabetes Patients, in Diabetes, ADA 292-OR Oral Presentation 2012, (Philadelphia, USA).